Optimization of a cisplatin model of chemotherapy-induced peripheral neuropathy in mice: Use of vitamin C and sodium bicarbonate pretreatments to reduce nephrotoxicity and improve animal health status

Molecular Pain

Volumn 10, Issue 1, 2014, Pages

  Guindon, Josée ^a   Deng, Liting ^a   Fan, Baochang ^a   Wager Miller, Jim ^a   Hohmann, Andrea G ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Chemotherapy; Cisplatin; Creatinine; Ibuprofen; Interleukins (IL 6, IL 1 , IL 10, TNF ); Morphine; NaHCO3 (sodium bicarbonate); Neuropathic pain; Resveratrol; Vitamin C

Indexed keywords

ASCORBIC ACID; BICARBONATE; CISPLATIN; CREATININE; GLUCOSE; IBUPROFEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; KETONE; MESSENGER RNA; MORPHINE; RESVERATROL; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; GLUCOSE BLOOD LEVEL; VITAMIN;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL HEALTH; ANTINOCICEPTION; ARTICLE; BLOOD PH; BODY TEMPERATURE; CANCER SURVIVAL; COLD SENSITIVITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HEALTH STATUS; KIDNEY FUNCTION; KIDNEY MASS; LUMBAR SPINAL CORD; MALE; MOUSE; NECK CANCER; NEPHROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; URINE PH; WEIGHT GAIN; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; HYPERALGESIA; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; BLOOD GLUCOSE; BODY TEMPERATURE; BODY WEIGHT; CISPLATIN; CREATININE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HEALTH STATUS; HYPERALGESIA; KETONES; MALE; MICE; MICE, INBRED C57BL; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM DISEASES; SODIUM BICARBONATE; VITAMINS;

EID: 84907409937     PISSN: 17448069     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-10-56     Document Type: Article

References (49)

1. Perry MC. Companion Handbook to the Chemotherapy Sourcebook 1999, Baltimore: Williams & Wilkins.
2. Pfister DG, Sum YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006, 24:1072-1078. 10.1200/JCO.2004.00.1792, 16505426.
3. Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012, 32:7091-7101. 10.1523/JNEUROSCI.0403-12.2012, 3366638, 22593077.
4. Zhao M, Isami K, Nakamura S, Shirakawa H, Nakagawa T, Kaneko S. Acute cold hypersensitivity characteristically induced by oxaliplatin is caused by the enhanced responsiveness of TRPA1 in mice. Mol Pain 2012, 8:55. 10.1186/1744-8069-8-55, 3495669, 22839205.
5. Verdú E, Vilches JJ, Rodríguez FJ, Ceballos D, Valero A, Navarro X. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 1999, 22:329-340. 10.1002/(SICI)1097-4598(199903)22:3<329::AID-MUS5>3.0.CO;2-8, 10086893.
6. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003, 182:12-20. 10.1016/S0014-4886(03)00003-7, 12821373.
7. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007, 81:468-479. 10.1016/j.lfs.2007.06.012, 17673260.
8. Guindon J, Hohmann AG. Use of sodium bicarbonate to promote weight gain, maintain body temperature, normalize renal functions and minimize mortality in rodents receiving the chemotherapeutic agent cisplatin. Neurosci Lett 2013, 544:41-46. 3682661, 23570729.
9. Ta LE, Bieber AJ, Carlton SM, Loprinzi CL, Low PA, Windebank AJ. Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain 2010, 6:15. 10.1186/1744-8069-6-15, 2848188, 20205720.
10. Ta LE, Schmelzer JD, Bieber AJ, Loprinzi CL, Sieck GC, Brederson JD, Low PA, Windebank AJ. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One 2013, 8:e54161. 10.1371/journal.pone.0054161, 3542321, 23326593.
11. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented?. Anticancer Drugs 1995, 6:369-383. 10.1097/00001813-199506000-00003, 7670134.
12. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9-17. 10.1007/PL00007853, 11954874.
13. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007, 334:115-124. 10.1097/MAJ.0b013e31812dfe1e, 17700201.
14. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992, 31:76-80. 10.1002/ana.410310114, 1543351.
15. Authier N, Fialip J, Eschalier A, Coudoré F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett 2000, 291:73-76. 10.1016/S0304-3940(00)01373-2, 10978577.
16. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009, 6:620-629. 10.1016/j.nurt.2009.07.003, 19789067.
17. Cata JP, Weng HR, Dougherty PM. Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res 2008, 1230:91-98. 2630495, 18657527.
18. Bacci G, Ferrari S, Longhi A, Forni C, Loro L, Beghelli C, Tremosini M, Versari M. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 2003, 10:851-857.
19. Mir O, Ropert S, Babinet A, Alexandre J, Larousserie F, Durand JP, Enkaoua E, Anract P, Goldwasser F. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol 2010, 66:1059-1063. 10.1007/s00280-010-1259-3, 20155268.
20. Do Amaral CL, Francescato HD, Coimbra TM, Costa RS, Darin JD, Antunes LM, Bianchi, Mde L. Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol 2008, 82:363-370. 10.1007/s00204-007-0262-x, 18026934.
21. Appenroth D, Fröb S, Kersten L, Splinter FK, Winnefeld K. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats. Arch Toxicol 1997, 71:677-683. 10.1007/s002040050444, 9363840.
22. Antunes LM, Darin JD, Bianchi MD. Protective effects of vitamin c against cisplatin- induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent study. Pharmacol Res 2000, 41:405-411. 10.1006/phrs.1999.0600, 10704263.
23. Behling EB, Sendão MC, Francescato HD, Antunes LM, Costa RS, Bianchi Mde L. Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol Rep 2006, 58:526-532.
24. Vera G, Chiarlone A, Martín MI, Abalo R. Altered feeding behaviour induced by long- term cisplatin in rats. Auton Neurosci 2006, 126-127:81-92.
25. Bhattacharyya S, Mehta P. The hepatoprotective potential of Spirulina and vitamin C supplemention in cisplatin toxicity. Food Funct 2012, 3:164-169. 10.1039/c1fo10172b, 22119940.
26. Oishi K, Hagiwara S, Koga S, Kawabe S, Uno T, Iwasaka H, Noguchi T. The vitamin E derivative, EPC-K1, suppresses inflammation during hepatic ischemia-reperfusion injury and exerts hepatoprotective effects in rats. J Surg Res 2012, 176:164-170. 10.1016/j.jss.2011.03.080, 22560539.
27. Hillyer EV, Quesenberry KE. Ferrets, rabbits and rodents; clinical medicine and surgery 1996, New York: Elsevier Health Science, 1.
28. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 2013, 67:94-109. 10.1016/j.phrs.2012.10.013, 3525790, 23127915.
29. Stratton JA, Braly PS, DiSaia PJ. Response of human adenocarcinoma to chemotherapy: as sole agents and in combination with sodium ibuprofen. Gynecol Oncol 1984, 18:145-149. 10.1016/0090-8258(84)90021-0, 6428983.
30. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non- steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998, 34:1250-1259. 10.1016/S0959-8049(98)00045-8, 9849488.
31. Roller A, Bähr OR, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun 1999, 259:600-605. 10.1006/bbrc.1999.0825, 10364464.
32. Keppler A, Gretz N, Schmidt R, Kloetzer HM, Groene HJ, Lelongt B, Meyer M, Sadick M, Pill J. Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int 2007, 71:74-78. 10.1038/sj.ki.5001988, 17082757.
33. Askew EW, Dohm GL, Huston RL. Fatty acid and ketone body metabolism in the rat: response to diet and exercise. J Nutri 1975, 105:1422-1432.
34. Koch DD, Feldbruegge DH. Optimized kinetic method for automated determination of beta-hydroxybutyrate. Clin Chem 1987, 33:1761-1766.
35. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012, 6:CD007543. 4048127, 22696371.
36. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 2007, 322:8-15. 10.1124/jpet.107.119792, 17400889.
37. Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B, Abbate M, Zoja C, Cassis P, Longaretti L, Rebulla P, Introna M, Capelli C, Benigni A, Remuzzi G, Lazzari L. Life-sparing effect of human cord blood- mesenchymal stem cells in experimental acute kidney injury. Stem Cells 2010, 28:513-522.
38. Reers S, Pfannerstill AC, Rades D, Maushagen R, Andratschke M, Pries R, Wollenberg B. Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer. Anticancer Res 2013, 33:2481-2489.
39. Sugama S, Takenouchi T, Sekiyama K, Kitani H, Hashimoto M. Immunological responses of astroglia in the rat brain under acute stress: interleukin 1 beta co- localized in astroglia. Neuroscience 2011, 192:429-437.
40. Dong Y, Wang S, Zhang T, Zhao X, Liu X, Cao L, Chi Z. Ascorbic acid ameliorates seizures and brain damage in rats through inhibiting autophagy. Brain Res 2013, 1535:115-123.
41. Zamani M, Soleimani M, Golab F, Mohamadzadeh F, Mehdizadeh M, Katebi M. NeuroProtective effects of adenosine receptor agonist coadministration with ascorbic acid on CA1 hippocampus in a mouse model of ischemia reperfusion injury. Metab Brain Dis 2013, 28:367-374. 10.1007/s11011-013-9408-0, 23640013.
42. Chang WW, Liu JJ, Liu CF, Liu WS, Lim YP, Cheng YJ, Lee CH. An extract of Rhodobacter sphaeroides reduces cisplatin-induced nephrotoxicity in mice. Toxins (Basel) 2013, 5:2353-2365. 10.3390/toxins5122353, 3873690, 24335753.
43. Kodama A, Watanabe H, Tanaka R, Kondo M, Chuang VT, Wu Q, Endo M, Ishima Y, Fukagawa M, Otagiri M, Maruyama T. Albumin fusion renders thioredoxin an effective anti- oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. Biochim Biophys Acta 1840, 2014:1152-1162.
44. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110. 10.1016/0304-3959(83)90201-4, 6877845.
45. Genedani S, Bernardi M, Bertolini A. Influence of antineoplastic drugs on morphine analgesia and on morphine tolerance. Eur J Pharmacol 1999, 367:13-17. 10.1016/S0014-2999(98)00966-2, 10082259.
46. Guindon J, De Léan A, Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 2006, 121:85-93. 10.1016/j.pain.2005.12.007, 16480822.
47. Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG. Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1-Dependent Withdrawal. Biol Psychiatry 2014, doi: 10.1016/j.biopsych.2014.04.009.
48. Ward SJ, Ramirez MD, Neelakantan H, Walker EA. Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. Anesth Analg 2011, 113:947-950. 3249239, 21737705.
49. Draper NR, Smith H. Applied regression analysis 1998, New York: Wiley.